Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
albumin-bound paclitaxel + carboplatin + apatinib + camrelizumab
- Development stage
- Unknown
- Lead developer
- Peking Union Medical College
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
This combination regimen consists of albumin-bound paclitaxel, carboplatin, apatinib, and camrelizumab. It is being investigated as a treatment for salivary gland carcinoma, specifically within a Phase 2 umbrella trial sponsored by Peking Union Medical College. The regimen combines cytotoxic chemotherapy (paclitaxel and carboplatin) with targeted therapy (apatinib) and immunotherapy (camrelizumab). Albumin-bound paclitaxel (nab-paclitaxel) is a microtubule inhibitor that prevents cancer cell division. Carboplatin is a platinum-based alkylating agent that interferes with DNA replication. Apatinib is a small-molecule tyrosine kinase inhibitor that selectively targets VEGFR-2, thereby inhibiting tumor angiogenesis. Camrelizumab is a monoclonal antibody that blocks the PD-1 receptor, enhancing the immune system's ability to detect and destroy tumor cells.
- Other names
- nab-paclitaxel + carboplatin + apatinib + camrelizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)DNATUBB (Tubulin (alpha and beta subunits))VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on albumin-bound paclitaxel + carboplatin + apatinib + camrelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on albumin-bound paclitaxel + carboplatin + apatinib + camrelizumab.